• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Gland Pharma jumps on debut
(10:08, 20 Nov 2020)
The stock was listed at Rs 1701, a premium of 13.4% to the initial public offer (IPO) price. So far the stock hit a high of Rs 1819.70 and low of 1701. On the BSE, 4.41 lakh shares were traded on the counter so far. While on NSE, 51.25 lakh shares exchanged hands.

IPO of Gland Pharma was subscribed 2.06 times. The issue opened for bidding on 9 November 2020 and it closed on 11 November 2020. The price band for the IPO was set at Rs 1490-1500 per share.

The qualified institutional buyers (QIBs) category was subscribed 6.40 times. The non-institutional investors category was subscribed 51% and the retail individual investors category was subscribed 24%.

The IPO consisted of fresh issue of shares amounting to Rs 1250 crore and an offer of sale of 3,48,63,635 shares by the selling shareholders.

Ahead of the IPO, the Hyderabad-based generic injectables-focused company allotted 1,29,59,089 shares to 70 anchor investors at Rs 1,500 per share aggregating to Rs 1,943.86 crore.

Overseas investors included SmallCap World Fund INC, Government of Singapore, The Nomura Trust And Banking Co and Goldman Sachs.

Out of the total 1,29,59,089 shares allotted to anchor investors, the company allocated 43,19,700 shares (or 33.33% of the total anchor allotment portion) to 18 domestic mutual funds through a total of 77 schemes.

The proceeds of the offer for sale shall be received by the selling shareholders. The company proposes to utilise the net proceeds of the fresh issue towards funding incremental working capital requirements; funding capital expenditure requirements; and general corporate purposes.

The company recorded net profit of Rs 313.59 crore and total income of Rs 916.28 crore in the quarter ended on 30 June 2020.

Hyderabad-based Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. It operates primarily under a business to business (B2B) model and it engaged in development, manufacturing and marketing of complex injectables.

Powered by Capital Market - Live News

DB (International) Stock Brokers Limited: SEBI Reg. No.-INZ000179035 / CDSL : IN-DP-CDSL-266-2004 MCX-SX:INE 260643233/21500(CD)
Daga Commodities Private Limited: SEBI Reg. No. INZ000028833
Investor Grievances Email ID: compliance@dbonline.in & investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries